

May 15, 2015



## **NEMUS Bioscience, Inc. to Attend Upcoming Investment Conferences**

COSTA MESA, CA -- (Marketwired) -- 05/15/15 -- NEMUS Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids for the treatment of glaucoma, announces that it has been invited to, and will attend, three investor conferences where they will present and conduct one-on-one meetings with investors in May and June.

### ***Conferences the company will attend:***

#### ***Marcum MicroCap Conference***

Date: May 28, 2015

Location: Grand Hyatt in New York, NY

Presentation: Thursday, May 28, 2015 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time)

Further information at [www.marcumllp.com](http://www.marcumllp.com)

#### ***LD Micro Invitational***

Date: June 1-3, 2015

Location: Luxe Sunset Hotel in Los Angeles, CA

Further information at <http://www.ldmicro.com/p/companies.html>

#### ***IGC-MTP Major Investment Themes Conference: Legal Cannabis Track***

Date: June 16, 2015

Location: The Harvard Club, New York, NY

Further information at <http://midtownpartners.com/2015-major-investment-themes-conference-legal-cannabis-track/>

Conference participation is by invitation only and registration is mandatory. For more information on the conferences or to schedule a one-on-one meeting with NEMUS Bioscience management, please contact the respective conference representatives.

### ***About NEMUS Bioscience, Inc.***

The Company is a biopharmaceutical company, headquartered in Costa Mesa, California, focused on the discovery, development, and commercialization of cannabis-based therapeutics for global markets with significant unmet medical needs. Utilizing certain proprietary technology licensed from the University of Mississippi, NEMUS is working to develop novel ways to deliver cannabis-based drugs for specific indications, with the aim of optimizing the clinical effects of such drugs, while limiting the potential adverse events. NEMUS's strategy is not limited to the sole use of either natural or synthetic inputs. The Company is led by a highly qualified team of executives with decades public company,

biopharmaceutical experience and significant background in early-stage drug development.

For more information, visit [www.nemusbioscience.com](http://www.nemusbioscience.com).

### ***Forward Looking Statements***

Statements in this document that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "believes," "can," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make.

Contact:

Investor Relations

Mike Cole

Vice President - MZ North America

Main: 949-259-4988

Mobile: 949-444-1341

[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)

[www.mzgroup.us](http://www.mzgroup.us)

Source: NEMUS Bioscience